Sam Colman, MSc

Sam Colman, MSc, is a Senior Director and real-world evidence (RWE) biostatistician who co-leads the RWE & Analytics service within Fortrea’s Market Access Consulting and HEOR group. He provides biostatistical leadership for real-world evidence (RWE) studies, health economic studies, and clinical outcome assessments, with a focus in Asia-Pac.

He has over 20 years of experience in various clinical trial and RWE study designs including randomized, parallel, cross-over, case-control, cross-sectional, prospective, and retrospective. He has also been involved in risk evaluation and mitigation strategies and PBAC submissions in Australia.

Sam brings detailed knowledge of FDA requirements related to data and analysis and has experience in complex statistical methods including multiple imputation, marginal structural modeling, non-parametric methods, propensity score methods, ROC curves, meta-analysis, and indirect comparisons. He is well published with over 80 publications in more than a dozen therapeutic areas.

Prior to joining Fortrea (formerly Labcorp and Covance), Sam was a Senior Project Statistician with Eli Lilly and worked in government, academia, and the pharmaceutical industry.

Sam earned an MSc in Biostatistics from the University of Sydney and a BS in Economics and a BS in Science (Honours in Statistics) from the Australian National University.